Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
GE HealthCare to Distribute Flyrcado via CDL Nuclear Tech
GE HealthCare announced a Distribution and Services Agreement (DSA) with CardioNavix, a part of the CDL Nuclear Technologies services group that provides end-to-end cardiac positron emission tomography (PET) imaging solutions to hospitals and outpatient practices throughout the U.S. Through this agreement, GE HealthCare aims to bring Flyrcado (flurpiridaz F18) injection, its novel cardiac PET imaging agent, to patients nationwide, including private cardiology practices and office and hospital imaging settings, expanding the reach of cardiac PET for the evaluation of known or suspected coronary artery disease.
Dr Batra’s Launches XOGEN Hair Regrowth Treatment in UAE
Dr Batra’s®, the world’s largest chain of homeopathy clinics, present in the UAE for the last 14 years, has introduced XOGEN Advance – the most advanced, non-invasive hair regrowth treatment designed to combat all types of hair loss and thinning. This breakthrough combines the latest exosome-based treatment with Dr Batra’s trusted legacy of safe and natural homeopathy.
Glenmark Starts Phase 3 Trial of Envafolimab for Stage III Non-Small Cell Lung Cancer
Glenmark Pharmaceuticals Ltd., a research-led, global pharmaceutical company, announced the initiation of a multi-country (ex-China) Phase 3 Clinical Trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, in patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC) in the neoadjuvant/adjuvant setting. The Company has received approval from the Drugs Controller General of India (DCGI) to begin patient enrollment and dosing in the country.
Rybrevant Plus Lazcluze Prevents Resistance in EGFR Lung Cancer
Johnson & Johnson has released new findings from the Phase 3 MARIPOSA trial showing that combining RYBREVANT with LAZCLUZE as a first-line treatment significantly lowers the risk of resistance caused by EGFR and MET mutations. This is compared to using osimertinib alone in patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have either exon 19 deletion or L858R mutations. These results support earlier data showing the treatment extends survival beyond four years—about a year longer than osimertinib—demonstrating its potential to change the disease’s progression by preventing acquired resistance. The findings were presented at the 2025 World Congress on Lung Cancer organized by the International Association for the Study of Lung Cancer.
Epigenic Therapeutics Raises $60 Million to Boost Epigenetic Drugs
Epigenic Therapeutics, a clinical-stage biotech company specializing in epigenetic-based drug development, has secured $60 million in a Series B funding round. The round was led by Lapam Capital and included continued support from previous investors Qiming Venture Partners and OrbiMed, as well as new participants such as IFSC and a prominent life sciences investment firm. The funds will primarily support the clinical advancement of EPI-003, aimed at a functional cure for chronic hepatitis B, and EPI-001, designed to treat high cholesterol. Additionally, the financing will accelerate multiple preclinical projects and enhance the company’s technology platforms, reinforcing Epigenic’s commitment to developing innovative epigenetic therapies.
To share your insights, please write to us at sudipto@intentamplify.com
